case 4: parp inhibitors for treating brca triple-negative breast cancer
Published 4 years ago • 181 plays • Length 3:46Download video MP4
Download video MP3
Similar videos
-
8:50
case 4: chemotherapy or parp inhibitors for brca tnbc
-
5:40
case 4: looking forward in brca metastatic tnbc
-
4:01
case 4: brca metastatic breast cancer
-
5:19
parp inhibitors for brca-associated tnbc
-
5:38
case 4: olympiad trial for brca metastatic tnbc
-
1:13
addressing the role of parp inhibitors in different breast cancer settings
-
1:27
parp inhibition improves outcomes in patients with brca-mutated ovarian cancer
-
4:19
treating brca breast cancer with parp inhibition
-
0:54
parp inhibitors advance beyond treatment of brca1/2-mutant gynecologic cancers
-
2:08
dr. lorusso on parp inhibitors in triple-negative breast cancer
-
5:18
parp inhibitors for brca-mutated tnbc
-
8:04
chemotherapy and parp inhibitors in bc
-
1:58
discussing targeted treatment with parp inhibitors for brca-mutant patients across tumor types
-
6:20
parp inhibitors for brca-mutated tnbc
-
2:48
immunomodulatory effects of parp inhibition in brca1-deficient triple-negative breast cancer
-
1:39:18
expanding the benefits of checkpoint inhibitors and targeted agents in triple-negative breast cancer
-
1:10
managing metastatic breast cancer and beyond using parp inhibitors
-
2:15
parp inhibitors in metastatic breast cancer: where are we now?
-
3:58
brca breast cancer: the advent of parp inhibitors